Citation: | WU Lei-lei, JIANG Fei, CHEN Xiao-wei, . Effect and mechanism of CagA on miR-142-3p expression regulation in gastric cancer cells[J]. Chinese Journal of Public Health, 2022, 38(12): 1566-1571. doi: 10.11847/zgggws1135771 |
[1] |
Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA:A Cancer Journal for Clinicians, 2016, 66(2): 115 – 132. doi: 10.3322/caac.21338
|
[2] |
Den Hoed CM, Kuipers EJ. Gastric cancer: how can we reduce the incidence of this disease?[J]. Current Gastroenterology Reports, 2016, 18(7): 34. doi: 10.1007/s11894-016-0506-0
|
[3] |
Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori[J]. International Journal of Cancer, 2015, 136(2): 487 – 490. doi: 10.1002/ijc.28999
|
[4] |
Bravo D, Hoare A, Soto C, et al. Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects[J]. World Journal of Gastroenterology, 2018, 24(28): 3071 – 3089. doi: 10.3748/wjg.v24.i28.3071
|
[5] |
Plummer M, De Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis[J]. The Lancet Global Health, 2016, 4(9): e609 – e616. doi: 10.1016/S2214-109X(16)30143-7
|
[6] |
Zhang RG, Duan GC, Fan QT, et al. Role of Helicobacter pylori infection in pathogenesis of gastric carcinoma[J]. World Journal of Gastrointestinal Pathophysiology, 2016, 7(1): 97 – 107. doi: 10.4291/wjgp.v7.i1.97
|
[7] |
Baj J, Forma A, Sitarz M, et al. Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment[J]. Cells, 2020, 10(1): 27. doi: 10.3390/cells10010027
|
[8] |
Alipour M. Molecular mechanism of Helicobacter pylori - induced gastric cancer[J]. Journal of Gastrointestinal Cancer, 2021, 52(1): 23 – 30. doi: 10.1007/s12029-020-00518-5
|
[9] |
Chen CZ. MicroRNAs as oncogenes and tumor suppressors[J]. The New England Journal of Medicine, 2005, 353(17): 1768 – 1771. doi: 10.1056/NEJMp058190
|
[10] |
Lin SB, Gregory RI. MicroRNA biogenesis pathways in cancer[J]. Nature Reviews Cancer, 2015, 15(6): 321 – 333. doi: 10.1038/nrc3932
|
[11] |
Dragomir MP, Kopetz S, Ajani JA, et al. Non - coding RNAs in GI cancers: from cancer hallmarks to clinical utility[J]. Gut, 2020, 69(4): 748 – 763. doi: 10.1136/gutjnl-2019-318279
|
[12] |
Hwang GR, Yuen JG, Ju JF. Roles of microRNAs in gastrointestinal cancer stem cell resistance and therapeutic development[J]. International Journal of Molecular Sciences, 2021, 22(4): 1624. doi: 10.3390/ijms22041624
|
[13] |
Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review[J]. Gastroenterology and Hepatology from Bed to Bench, 2015, 8(S1): S6 – S14.
|
[14] |
Shi YY, Yang ZW, Zhang T, et al. SIRT1 - targeted miR - 543 autophagy inhibition and epithelial - mesenchymal transition promotion in Helicobacter pylori CagA - associated gastric cancer[J]. Cell Death and Disease, 2019, 10(9): 625. doi: 10.1038/s41419-019-1859-8
|
[15] |
马小丽. 幽门螺杆菌CagA和VacA重组蛋白的表达、纯化及抗原性检测[D]. 郑州: 郑州大学, 2011.
|
[16] |
Yang J, Song H, Cao K, et al. Comprehensive analysis of Helicobacter pylori infection - associated diseases based on miRNA - mRNA interaction network[J]. Briefings in Bioinformatics, 2019, 20(4): 1492 – 1501. doi: 10.1093/bib/bby018
|
[17] |
Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta - analysis[J]. Gastroenterology, 2016, 150(5): 1113 – 1124.e5. doi: 10.1053/j.gastro.2016.01.028
|
[18] |
Lee YC, Chen THH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community - based study of gastric cancer prevention[J]. Gut, 2013, 62(5): 676 – 682. doi: 10.1136/gutjnl-2012-302240
|
[19] |
Chen ZH, Chen HJ, Yu L, et al. Bioinformatic identification of key pathways, hub genes, and microbiota for therapeutic intervention in Helicobacter pylori infection[J]. Journal of Cellular Physiology, 2021, 236(2): 1158 – 1183. doi: 10.1002/jcp.29925
|
[20] |
Xu ZP, Li Z, Wang WZ, et al. MIR - 1265 regulates cellular proliferation and apoptosis by targeting calcium binding protein 39 in gastric cancer and, thereby, impairing oncogenic autophagy[J]. Cancer Letters, 2019, 449: 226 – 236. doi: 10.1016/j.canlet.2019.02.026
|
[21] |
Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103(7): 2257 – 2261. doi: 10.1073/pnas.0510565103
|
[22] |
Liu XW, Cai H, Sheng WQ, et al. microRNAs expression profile related with response to preoperative radiochemotherapy in patients with locally advanced gastric cancer[J]. BMC Cancer, 2018, 18(1): 1048. doi: 10.1186/s12885-018-4967-4
|
[23] |
Inoue T, Iinuma H, Ogawa E, et al. Clinicopathological and prognostic significance of microRNA - 107 and its relationship to DICER1 mRNA expression in gastric cancer[J]. Oncology Reports, 2012, 27(6): 1759 – 1764.
|
[24] |
Han J, Yu JL, Ling ZQ. Screening of specific miRNA in early gastric cancer[J]. Chinese Journal of Gastrointestinal Surgery, 2014, 17(2): 175 – 179.
|
[25] |
Peng L, Sang GH, Wei SC, et al. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR - 142 - 3p/ROCK2[J]. Molecular Cancer, 2020, 19(1): 156. doi: 10.1186/s12943-020-01270-x
|
[26] |
Xu HF, Huang TJ, Yang Q, et al. Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K - regulatory subunit PIK3R2 expression[J]. Cancer Management and Research, 2019, 11: 5557 – 5572. doi: 10.2147/CMAR.S203060
|
[27] |
Liu W, Jiang DD, Gong FY, et al. miR-210-5p promotes epithelial - mesenchymal transition by inhibiting PIK3R5 thereby activating oncogenic autophagy in osteosarcoma cells[J]. Cell Death and Disease, 2020, 11(2): 93. doi: 10.1038/s41419-020-2270-1
|
[28] |
Bu QG, You FP, Pan GZ, et al. MiR - 125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD[J]. Biomedicine and Pharmacotherapy, 2017, 88: 443 – 448. doi: 10.1016/j.biopha.2016.11.090
|